NASDAQ:DMK

DMK Pharmaceuticals (DMK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.04
$0.58
52-Week Range
N/A
Volume
24.16 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
DMK stock logo

About DMK Pharmaceuticals Stock (NASDAQ:DMK)

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.

DMK Stock News Headlines

This AI Trade Machine Made 1,729%* (With 89% Wins)
This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?
This AI Trade Machine Made 1,729%* (With 89% Wins)
This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?
DMK Pharmaceuticals Corp DMKPQ
DMK Pharmaceuticals Corp (DMKPQ)
DMK Pharmaceuticals Corporation (DMKPQ)
DMK Pharmaceuticals Corporation
See More Headlines
Receive DMK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DMK Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DMK
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,480,000.00
Net Margins
-630.85%
Pretax Margin
-600.29%

Debt

Sales & Book Value

Annual Sales
$3.62 million
Book Value
($0.38) per share

Miscellaneous

Free Float
9,506,000
Market Cap
$2.34 million
Optionable
No Data
Beta
1.11
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Seth Abraham Cohen (Age 61)
    Chief Financial Officer
  • Mr. John W. Dorbin Jr. (Age 53)
    General Counsel Corporate Secretary
  • Mr. Eddie Wabern Glover (Age 74)
    Chief Executive Officer of US Compounding Inc

DMK Stock Analysis - Frequently Asked Questions

Should I buy or sell DMK Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DMK Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMK shares.
View DMK analyst ratings
or view top-rated stocks.

What is DMK Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12 month price objectives for DMK Pharmaceuticals' shares. Their DMK share price targets range from $1.50 to $1.50. On average, they predict the company's share price to reach $1.50 in the next year.
View analysts price targets for DMK
or view top-rated stocks among Wall Street analysts.

This page (NASDAQ:DMK) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners